20:22 , Jun 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Hepatitis C virus (HCV) Cell culture studies suggest inhibiting ERN1 could help treat HCV infection. In HCV patients, levels of ERN1 activity in the liver were higher than in HCV-negative liver transplant patients. In an...
07:00 , Mar 26, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: HCV NS4B transmembrane protein

Infectious disease INDICATION: Hepatitis C virus (HCV) In vitro studies suggest imidazo[2,1-b]thiazole-based inhibitors of HCV NS4B transmembrane protein could be combined with other HCV-targeting antivirals to treat HCV infection. Chemical synthesis and in vitro testing identified two...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

VGX-6150: Phase I started

Inovio said its VGX affiliate began an open-label, dose-escalation, Korean Phase I trial to evaluate 4 monthly vaccinations with 1, 3 and 6 mg VGX-6150 in 18 patients with chronic HCV infection who failed previous...
08:00 , Feb 4, 2010 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease HCV HCV non-structural protein 4B (NS4B) In vitro studies identified small molecule NS4B inhibitors that could...
07:00 , Aug 17, 2009 |  BC Week In Review  |  Clinical News

Clemizole hydrochloride: Phase Ib started

Eiger began the open-label, Australian and New Zealand Phase Ib CLEAN-1 trial to evaluate 100 mg oral clemizole given twice daily for 28 days in 12 treatment-naïve patients. Eiger has exclusive, worldwide rights to HCV...
07:00 , Aug 10, 2009 |  BC Week In Review  |  Company News

Eiger, Stanford University deal

Eiger received exclusive, worldwide rights to the university's HCV technology that is focused on multiple targets, including HCV non-structural protein 4B. The technology was discovered by Eiger founder and university researcher, Jeffrey Glenn. Financial...
00:25 , Oct 31, 2008 |  BC Extra  |  Company News

GSK to acquire Genelabs

GlaxoSmithKline (LSE:GSK; NYSE:GSK) plans to acquire Genelabs (NASDAQ:GNLB) in a tender offer of $1.30 per share, or $57 million in cash. The price is a 465% premium to Genelabs' close of $0.23 on Wednesday, the...
00:19 , Sep 27, 2007 |  BC Extra  |  Financial News

Genelabs raises $23.7 million

GNLB raised $23.7 million in a registered direct offering of 12.9 million units at $1.84 per unit. Each unit consists of one share and a five-year warrant to purchase a fifth of a share at...